Flagship Pioneering, LLC Long-Term Concentrated

Location: Cambridge, MA

CIK: 0001400240 · Show all filings

Period: Q1 2020 (← Previous) (Next →)

Filing Date: May 14, 2020

Total Value: $2.133B (100.0% shares, 0.0% debt)

Holdings (8)

MRNA Moderna Inc 71.4%

Value $1.524B Shares 50,871,524 Est. Cost $16.43 Unrealized +40.0%

— Rubius Therapeutics Inc 8.0%

Value $170M Shares 38,296,526 Est. Cost $24.00 Unrealized —

DNLI Denali Therapeutics Inc 6.5%

Value $140M Shares 7,980,263 Est. Cost $17.97 Unrealized +16.1%

KLDO Kaleido Biosciences Inc 5.0%

Value $107M Shares 17,360,710 Est. Cost $13.76 Unrealized -52.6%

— Seres Therapeutics Inc 3.6%

Value $77.01M Shares 21,571,764 Est. Cost $8.55 Unrealized —

— Evelo Biosciences Inc 3.2%

Value $68.56M Shares 18,233,403 Est. Cost $11.80 Unrealized —

— Axcella Health Inc 1.4%

Value $29.92M Shares 8,748,414 Est. Cost $9.31 Unrealized —

— Syros Pharmaceuticals Inc 0.8%

Value $17.43M Shares 2,938,494 Est. Cost $13.87 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
MRNA	Moderna Inc	50,871,524	$1.524B	71.4%	$16.43	+40.0%	COM	60770K107
—	Rubius Therapeutics Inc	38,296,526	$170M	8.0%	$24.00	—	COM	78116T103
DNLI	Denali Therapeutics Inc	7,980,263	$140M	6.5%	$17.97	+16.1%	COM	24823R105
KLDO	Kaleido Biosciences Inc	17,360,710	$107M	5.0%	$13.76	-52.6%	COM	483347100
—	Seres Therapeutics Inc	21,571,764	$77.01M	3.6%	$8.55	—	COM	81750R102
—	Evelo Biosciences Inc	18,233,403	$68.56M	3.2%	$11.80	—	COM	299734103
—	Axcella Health Inc	8,748,414	$29.92M	1.4%	$9.31	—	COM	05454B105
—	Syros Pharmaceuticals Inc	2,938,494	$17.43M	0.8%	$13.87	—	COM	87184Q107